REGENERON PHARMACEUTICALS, INC. Payments to Acquire Productive Assets
REGENERON PHARMACEUTICALS, INC. (REGN) reported Payments to Acquire Productive Assets of $470.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2026-06-30 was $240.20M, a 9.68% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2026-03-31 was $230.60M, a 0.57% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2025-12-31 was $248.70M, a 24.60% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2025-09-30 was $201.40M, a 16.74% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2025 was $898.40M, a 18.85% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2024 was $755.90M, a 5.19% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2023 was $718.60M, a 21.78% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2022 was $590.10M, a 6.92% increase from fiscal 2021.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 3 month as first filed | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 6 month as first filed | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 9 month as first filed | Payments to Acquire Productive Assets 12 month | Payments to Acquire Productive Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $240.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $470.80M 10-Q · filed 2026-07-30 | $719.50M derived: sum of 3 quarters · filed 2026-07-30 | $920.90M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $230.60M 10-Q · filed 2026-04-29 | $479.30M derived: sum of 2 quarters · filed 2026-04-29 | $680.70M derived: sum of 3 quarters · filed 2026-04-29 | $899.70M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $248.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $450.10M derived: sum of 2 quarters · filed 2026-02-04 | $669.10M derived: sum of 3 quarters · filed 2026-07-30 | $898.40M 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $201.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $420.40M derived: sum of 2 quarters · filed 2026-07-30 | $649.70M 10-Q · filed 2025-10-28 | $849.30M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $219.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $448.30M 10-Q · filed 2026-07-30 | $647.90M derived: sum of 3 quarters · filed 2026-07-30 | $889.80M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $229.30M 10-Q · filed 2026-04-29 | $428.90M derived: sum of 2 quarters · filed 2026-04-29 | $670.80M derived: sum of 3 quarters · filed 2026-04-29 | $851.30M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $199.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $441.50M derived: sum of 2 quarters · filed 2026-02-04 | $622.00M derived: sum of 3 quarters · filed 2026-02-04 | $755.90M 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $241.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $422.40M derived: sum of 2 quarters · filed 2025-10-28 | $556.30M 10-Q · filed 2025-10-28 | $807.70M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $180.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $314.40M 10-Q · filed 2025-08-01 | $565.80M derived: sum of 3 quarters · filed 2026-02-04 | $741.80M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $133.90M 10-Q · filed 2025-04-29 | $385.30M derived: sum of 2 quarters · filed 2026-02-04 | $561.30M derived: sum of 3 quarters · filed 2026-02-04 | $674.30M derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $251.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $427.40M derived: sum of 2 quarters · filed 2026-02-04 | $540.40M derived: sum of 3 quarters · filed 2026-02-04 | $718.60M 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $176.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $289.00M derived: sum of 2 quarters · filed 2024-10-31 | $467.20M 10-Q · filed 2024-10-31 | $619.40M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $113.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $291.20M 10-Q · filed 2024-08-01 | $443.40M derived: sum of 3 quarters · filed 2025-02-05 | $585.90M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $178.20M 10-Q · filed 2024-05-02 | $330.40M derived: sum of 2 quarters · filed 2025-02-05 | $472.90M derived: sum of 3 quarters · filed 2025-02-05 | $626.50M derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $152.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $294.70M derived: sum of 2 quarters · filed 2025-02-05 | $448.30M derived: sum of 3 quarters · filed 2025-02-05 | $590.10M 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $142.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $296.10M derived: sum of 2 quarters · filed 2023-11-02 | $437.90M 10-Q · filed 2023-11-02 | $592.80M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $153.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $295.40M 10-Q · filed 2023-08-03 | $450.30M derived: sum of 3 quarters · filed 2024-02-05 | $583.50M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $141.80M 10-Q · filed 2023-05-04 | $296.70M derived: sum of 2 quarters · filed 2024-02-05 | $429.90M derived: sum of 3 quarters · filed 2024-02-05 | $578.40M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $154.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $288.10M derived: sum of 2 quarters · filed 2024-02-05 | $436.60M derived: sum of 3 quarters · filed 2024-02-05 | $551.90M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $133.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $281.70M derived: sum of 2 quarters · filed 2022-11-03 | $397.00M 10-Q · filed 2022-11-03 | $558.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $148.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $263.80M 10-Q · filed 2022-08-03 | $425.20M derived: sum of 3 quarters · filed 2023-02-06 | $578.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $115.30M 10-Q · filed 2022-05-04 | $276.70M derived: sum of 2 quarters · filed 2023-02-06 | $429.90M derived: sum of 3 quarters · filed 2023-02-06 | $559.80M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $161.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $314.60M derived: sum of 2 quarters · filed 2023-02-06 | $444.50M derived: sum of 3 quarters · filed 2023-02-06 | $614.60M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $153.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $283.10M derived: sum of 2 quarters · filed 2021-11-04 | $453.20M 10-Q · filed 2021-11-04 | $592.20M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $129.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $300.00M 10-Q · filed 2021-08-05 | $439.00M derived: sum of 3 quarters · filed 2022-02-07 | $560.70M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $170.10M 10-Q · filed 2021-05-06 | $309.10M derived: sum of 2 quarters · filed 2022-02-07 | $430.80M derived: sum of 3 quarters · filed 2022-02-07 | $525.40M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $139.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $260.70M derived: sum of 2 quarters · filed 2022-02-07 | $355.30M derived: sum of 3 quarters · filed 2022-02-07 | $429.60M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $121.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $216.30M derived: sum of 2 quarters · filed 2020-11-05 | $290.60M 10-Q · filed 2020-11-05 | $376.10M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $94.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $168.90M 10-Q · filed 2020-08-05 | $254.40M derived: sum of 3 quarters · filed 2021-02-08 | $360.60M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $74.30M 10-Q · filed 2020-05-05 | $159.80M derived: sum of 2 quarters · filed 2021-02-08 | $266.00M derived: sum of 3 quarters · filed 2021-02-08 | $378.00M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $85.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $191.70M derived: sum of 2 quarters · filed 2021-02-08 | $303.70M derived: sum of 3 quarters · filed 2021-02-08 | $383.10M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $106.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $218.20M derived: sum of 2 quarters · filed 2019-11-05 | $297.60M 10-Q · filed 2019-11-05 | $297.64M 10-Q · filed 2018-11-06 | $405.24M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $112.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $191.40M 10-Q · filed 2019-08-06 | $191.39M 10-Q · filed 2018-08-02 | $299.04M derived: sum of 3 quarters · filed 2020-02-07 | $358.69M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $79.40M 10-Q · filed 2019-05-07 | $79.38M 10-Q · filed 2018-05-03 | $187.04M derived: sum of 2 quarters · filed 2020-02-07 | $246.69M derived: sum of 3 quarters · filed 2020-02-07 | $301.54M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $107.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $167.29M derived: sum of 2 quarters · filed 2020-02-07 | $222.14M derived: sum of 3 quarters · filed 2020-02-07 | $272.60M 10-K · filed 2020-02-07 | $272.63M 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $59.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $114.50M derived: sum of 2 quarters · filed 2018-11-06 | $164.96M 10-Q · filed 2018-11-06 | $315.38M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $54.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $105.31M 10-Q · filed 2018-08-02 | $255.72M derived: sum of 3 quarters · filed 2019-02-07 | $374.28M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $50.46M 10-Q · filed 2018-05-03 | $200.88M derived: sum of 2 quarters · filed 2019-02-07 | $319.43M derived: sum of 3 quarters · filed 2019-02-07 | $458.27M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $150.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $268.97M derived: sum of 2 quarters · filed 2019-02-07 | $407.81M derived: sum of 3 quarters · filed 2019-02-07 | $511.90M 10-K · filed 2019-02-07 | $511.94M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $118.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $257.39M derived: sum of 2 quarters · filed 2017-11-08 | $361.49M 10-Q · filed 2017-11-08 | $539.26M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $138.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $242.93M 10-Q · filed 2017-08-03 | $420.71M derived: sum of 3 quarters · filed 2018-02-08 | $566.81M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $104.09M 10-Q · filed 2017-05-04 | $281.87M derived: sum of 2 quarters · filed 2018-02-08 | $427.97M derived: sum of 3 quarters · filed 2018-02-08 | $667.87M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $177.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $323.88M derived: sum of 2 quarters · filed 2018-02-08 | $563.77M derived: sum of 3 quarters · filed 2018-02-08 | $677.93M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $146.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $385.99M derived: sum of 2 quarters · filed 2016-11-04 | $500.15M 10-Q · filed 2016-11-04 | $617.70M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $239.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $354.06M 10-Q · filed 2016-08-04 | $471.60M derived: sum of 3 quarters · filed 2017-02-09 | $551.37M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $114.16M 10-Q · filed 2016-05-05 | $231.70M derived: sum of 2 quarters · filed 2017-02-09 | $311.47M derived: sum of 3 quarters · filed 2017-02-09 | $382.35M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $117.54M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $197.31M derived: sum of 2 quarters · filed 2017-02-09 | $268.18M derived: sum of 3 quarters · filed 2017-02-09 | $333.01M 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | $79.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $150.64M derived: sum of 2 quarters · filed 2015-11-04 | $215.46M 10-Q · filed 2015-11-04 | $284.44M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $70.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $135.69M 10-Q · filed 2015-08-04 | $204.67M derived: sum of 3 quarters · filed 2016-02-11 | $236.36M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $64.82M 10-Q · filed 2015-05-07 | $133.80M derived: sum of 2 quarters · filed 2016-02-11 | $165.49M derived: sum of 3 quarters · filed 2016-02-11 | $199.94M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $68.98M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $100.67M derived: sum of 2 quarters · filed 2016-02-11 | $135.12M derived: sum of 3 quarters · filed 2016-02-11 | $156.32M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $31.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $66.14M derived: sum of 2 quarters · filed 2014-11-04 | $87.35M 10-Q · filed 2014-11-04 | $102.51M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $34.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $55.66M 10-Q · filed 2014-08-05 | $70.82M derived: sum of 3 quarters · filed 2015-02-12 | $81.07M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $21.20M 10-Q · filed 2014-05-08 | $36.37M derived: sum of 2 quarters · filed 2015-02-12 | $46.61M derived: sum of 3 quarters · filed 2015-02-12 | $59.48M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $25.41M derived: sum of 2 quarters · filed 2015-02-12 | $38.28M derived: sum of 3 quarters · filed 2015-02-12 | $49.34M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | $10.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $23.12M derived: sum of 2 quarters · filed 2013-11-05 | $34.17M 10-Q · filed 2013-11-05 | $45.46M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | $12.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $23.93M 10-Q · filed 2013-08-06 | $35.22M derived: sum of 3 quarters · filed 2014-02-13 | $44.11M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | $11.05M 10-Q · filed 2013-05-03 | $22.34M derived: sum of 2 quarters · filed 2014-02-13 | $31.24M derived: sum of 3 quarters · filed 2014-02-13 | $46.11M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $20.19M derived: sum of 2 quarters · filed 2014-02-13 | $35.05M derived: sum of 3 quarters · filed 2014-02-13 | $57.22M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | $8.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $23.76M derived: sum of 2 quarters · filed 2012-10-24 | $45.93M 10-Q · filed 2012-10-24 | $78.19M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $14.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $37.03M 10-Q · filed 2012-07-25 | $69.29M derived: sum of 3 quarters · filed 2013-02-15 | $91.39M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $22.17M 10-Q · filed 2012-04-26 | $54.43M derived: sum of 2 quarters · filed 2013-02-15 | $76.53M derived: sum of 3 quarters · filed 2013-02-15 | $99.11M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $32.26M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $54.37M derived: sum of 2 quarters · filed 2013-02-15 | $76.95M derived: sum of 3 quarters · filed 2013-02-15 | $99.69M 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $22.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $44.68M derived: sum of 2 quarters · filed 2011-10-27 | $67.43M 10-Q · filed 2011-10-27 | $89.74M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $22.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $45.32M 10-Q · filed 2011-07-28 | $67.64M derived: sum of 3 quarters · filed 2012-02-21 | $89.97M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $22.74M 10-Q · filed 2011-05-03 | $45.06M derived: sum of 2 quarters · filed 2012-02-21 | $67.39M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | $22.32M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $44.65M derived: sum of 2 quarters · filed 2012-02-21 | $97.32M 10-K · filed 2012-02-21 | |||||
| 2009-09-30 | $22.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $75.00M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $52.67M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $34.86M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |